Orbimed Advisors LLC bought $12M of PRLD
director, owner at Prelude Therapeutics Inc. 2,815,315 shares at an average of $4.44, traded Apr 21, 2026, filed Apr 23, 2026.
Score components
- +15RoleDirector
- +25Trade size$12.5M at market
- +6Relative to holdingsHoldings up 28%
- +4Price context16% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- -5Track recordMedian 6-month excess return -26% over 4 past buys
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.0%, 3m -10.7%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000947871-26-000461, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 21, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,689,189 | $4.44 | $7.5M | 11,808,945 | Apr 23, 2026 |
| Apr 21, 2026 | POpen-market purchase Common Stockindirect: See footnotes | +1,126,126 | $4.44 | $5.0M | 1,126,126 | Apr 23, 2026 |
Related signals
Other insiders at Prelude Therapeutics Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 58Moderate | Prelude Therapeutics Inc | David P Bonita director, owner | $12M 2,815,315 shares | +28% | |
| 29Weak | PRLDbuy Prelude Therapeutics Inc | Andrew Combs Chief Chemistry Officer | $69k 100,000 shares | +26% | |
| 45Moderate | Prelude Therapeutics Inc | Andrew Combs Chief Chemistry Officer | $86k 63,075 shares | +20% | |
| 47Moderate | Prelude Therapeutics Inc | Bryant David Lim CLO, Interim CFO, Corp Sec. | $23k 25,000 shares | +1042% | |
| 53Moderate | Prelude Therapeutics Inc | Krishna Vaddi CEO | $99k 106,888 shares | +10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.